Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy).

Publication date: Jun 02, 2021

Improved understanding of tumor immunology has enabled the development of therapies that harness the immune system and prevent immune escape. Numerous clinical trials and real-world experience has provided evidence of the potential for long-term survival with immunotherapy in various types of malignancy. Recurring observations with immuno-oncology agents include their potential for clinical application across a broad patient population with different tumor types, conventional and unconventional response patterns, durable responses, and immune-related adverse events. Despite the substantial achievements to date, a significant proportion of patients still fail to benefit from current immunotherapy options, and ongoing research is focused on transforming non-responders to responders through the development of novel treatments, new strategies to combination therapy, adjuvant and neoadjuvant approaches, and the identification of biomarkers of response. These topics were the focus of the virtual Immunotherapy Bridge (December 2nd-3rd, 2020), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer and are summarised in this report.

Open Access PDF

Concepts Keywords
Biomarkers Immunotherapy
Immunology Clinical medicine
Italy Cancer immunotherapy
Naples Virotherapy
Therapy Oncology
Tumor

Semantics

Type Source Name
disease MESH tumor
disease MESH development
pathway REACTOME Immune System
disease MESH Melanoma
pathway KEGG Melanoma
drug DRUGBANK Formaldehyde
disease MESH death
drug DRUGBANK Pembrolizumab
disease MESH diagnosis
drug DRUGBANK Trestolone
disease MESH pathology
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Indoleacetic acid
disease MESH renal carcinoma
disease MESH plant based diet
drug DRUGBANK Adenosine
disease MESH squamous cell carcinoma
disease MESH HNSCC
drug DRUGBANK Nivolumab
disease MESH neck cancer
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Coenzyme M
drug DRUGBANK Platinum
drug DRUGBANK Cytidine-5′-Monophosphate
drug DRUGBANK Cycloserine
drug DRUGBANK Talimogene laherparepvec
disease MESH recurrence
drug DRUGBANK Naproxen
disease MESH syndrome
disease MESH Angiosarcoma
drug DRUGBANK Ipilimumab
drug DRUGBANK Hexocyclium
drug DRUGBANK Atezolizumab
drug DRUGBANK Paclitaxel
drug DRUGBANK Gemcitabine
drug DRUGBANK Carboplatin
drug DRUGBANK Methotrexate
drug DRUGBANK Cetuximab
drug DRUGBANK Avelumab
disease MESH moPD
disease MESH oropharyngeal cancer
disease MESH prostate cancer
pathway KEGG Prostate cancer
disease MESH immune tolerance
pathway KEGG Apoptosis
disease MESH tryptophan
drug DRUGBANK L-Tryptophan
disease MESH ovarian cancer
drug DRUGBANK Epacadostat
disease MESH carcinoma
drug DRUGBANK Nicotinamide
drug DRUGBANK Serotonin
pathway KEGG Mismatch repair
disease MESH colorectal tumor
drug DRUGBANK Cobimetinib
drug DRUGBANK Regorafenib
pathway KEGG Colorectal cancer
drug DRUGBANK Rasagiline
drug DRUGBANK MCC
disease MESH hypoxia
drug DRUGBANK Axicabtagene ciloleucel
disease MESH B cell lymphoma
disease MESH inflammation
disease MESH Breast cancer
pathway KEGG Breast cancer
drug DRUGBANK Isoxaflutole
drug DRUGBANK Letrozole
disease MESH estrogen
drug DRUGBANK Ribociclib
drug DRUGBANK Palbociclib
drug DRUGBANK Tamoxifen
drug DRUGBANK Esomeprazole
drug DRUGBANK Rituximab
disease MESH non Hodgkin lymphoma
drug DRUGBANK Obinutuzumab
drug DRUGBANK Lenalidomide
disease MESH lymphoma
disease MESH Hodgkin lymphoma
drug DRUGBANK Brentuximab vedotin
drug DRUGBANK Tisagenlecleucel
disease MESH mantle cell lymphoma
drug DRUGBANK L-Tyrosine
drug DRUGBANK Methionine
disease MESH autoimmunity
disease MESH Microsatellite instability
disease MESH lung cancer
disease MESH Small cell lung cancer
pathway KEGG Small cell lung cancer
disease MESH Triple negative breast cancer
drug DRUGBANK Peracetic acid
drug DRUGBANK Diethylstilbestrol
drug DRUGBANK Dantron
drug DRUGBANK Ranitidine
drug DRUGBANK Sulfasalazine
disease MESH Mismatch repair deficiency
disease MESH noma
drug DRUGBANK Bismuth subgallate
disease MESH diffuse large B cell lymphoma
disease MESH Leukemia

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *